Skip to content
Clinical Trials – home
Not yet recruiting

Phase 2 Study of ABBV-295 and Risankizumab in Adults with Moderate to Severe Psoriasis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial focuses on adults with moderate to severe Psoriasis. It evaluates two investigational injectable medicines, ABBV-295 and ABBV-066, the latter containing the active protein RISANKIZUMAB, compared with a placebo. The purpose of the study is to determine how well these agents improve skin lesions and how safe they are.

Participants receive a series of injections over several weeks while attending regular clinic visits. At each visit, doctors check the skin, record any side effects, and measure body weight. The study continues for a few months, after which the data are collected for analysis.

Improvement is measured using the Psoriasis Area and Severity Index, a scoring system that rates the redness, thickness and area of skin plaques; a high score means more severe disease, and a reduction indicates improvement. Safety is monitored by recording any adverse events, which are any unwanted medical occurrences during the trial.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessment

    After joining the study, you will undergo a baseline visit that includes a review of your medical history, a physical examination, and measurement of your skin condition using the Psoriasis Area and Severity Index (PASI).

    Your body weight will also be recorded at this visit.

  2. Step 2

    Randomization

    Based on the study design, you will be randomly assigned to receive one of the following: the investigational drug ABBV-295, the investigational drug ABBV-066 (which contains the active substance risankizumab), or a matching placebo.

    The assignment is made by the study team and you will not know which product you receive.

  3. Step 3

    First Injection

    You will receive the first dose of the assigned product by injection.

    Both ABBV-295 and ABBV-066 are provided as a solution for injection with a concentration of 0.00 mg per millilitre, administered according to the study protocol.

  4. Step 4

    Ongoing Treatment Visits

    You will return to the study site for additional injection visits at the intervals specified by the protocol.

    Each visit will include an injection of the same product you received at the first visit, using the same concentration and route (injection).

  5. Step 5

    Efficacy Evaluations

    During the treatment period, your skin condition will be reassessed regularly with the PASI score.

    The study aims to determine whether you achieve at least a 90 % improvement from baseline (PASI 90) or complete clearance (PASI 100).

  6. Step 6

    Safety Monitoring

    At each visit, you will be asked about any new symptoms or side effects, which are recorded as adverse events (AEs).

    Your vital signs and overall health will be checked to ensure the medication is well tolerated.

  7. Step 7

    End‑of‑Study Visit

    At the conclusion of the trial, a final assessment will be performed, including a last PASI measurement, body‑weight check, and safety evaluation.

    All study data will be collected, and you will be informed about the overall study results.

Who can join the trial?

5 criteria

  • Have a doctor’s diagnosis of chronic plaque psoriasis (a type of skin rash) with or without psoriatic arthritis (joint inflammation) that has lasted at least 6 months before the first study visit.
  • Show stable, moderate to severe disease at both the screening and baseline visits, meaning the rash covers at least 10% of the body surface area (the total skin area), the doctor’s visual rating called the Static Physician's Global Assessment is 3 or higher, and the PASI score (a number that measures how bad the psoriasis is) is 12 or higher.
  • Be considered a candidate for systemic therapy (medicine that works throughout the whole body) or phototherapy (treatment that uses special light), as decided by the study doctor.
  • Be within the age range defined by the trial (the study includes both children and adults as specified in the protocol).
  • Be either male or female, as both sexes are allowed to participate.

Who cannot join the trial?

3 criteria

  • People who have any type of psoriasis that is not the common “chronic plaque” form (for example, pustular psoriasis, palm‑plantar pustulosis, acrodermatitis of Hallopeau, erythrodermic psoriasis, or guttate psoriasis) cannot join the study.
  • Anyone who has ever had psoriasis caused or worsened by medication (known as drug‑induced psoriasis) is not eligible.
  • People with other active, ongoing skin conditions that cause inflammation (such as severe eczema with thickened skin, called hyperkeratotic eczema) and are not psoriasis, even if they also have or do not have psoriatic arthritis (PsA), cannot participate because these conditions could affect the study results.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • ABBV-295

    is an experimental medicine that is given by injection. In this study it is being tested to see if it can improve the skin symptoms of adults with moderate to severe psoriasis. The drug is supplied as a liquid that can be injected directly into the body. Researchers are looking at how well it works on its own or together with other treatments, and they are also checking its safety.

  • ABBV-066

    is the study code for a medicine called risankizumab, which is also given by injection. It is provided in a pre‑filled syringe for easy use. In the trial, this medicine is being evaluated for its ability to reduce the redness, thickness, and scaling of psoriasis‑affected skin. The study will measure how effective it is and monitor any side effects.

What is already known about the treatment

ABBV-295 - This investigational drug is provided as a sterile solution for injection that is given by a healthcare professional through a needle, usually under the skin. It is currently in early‑phase clinical trials and has not yet been approved for regular medical use. The drug is being studied for the treatment of moderate to severe plaque psoriasis, aiming to reduce skin redness and scaling. It works by binding to a specific protein involved in the body’s inflammatory response, classifying it as an experimental monoclonal antibody biologic. Risankizumab - Risankizumab is supplied as a pre‑filled syringe containing a clear solution that is injected under the skin by a trained professional. It is an approved medication for adult patients with moderate to severe plaque psoriasis and is listed in medical literature as an effective therapy. The drug targets and blocks interleukin‑23, a key molecule that drives the inflammation seen in psoriasis, and is classified as a humanized IgG1 monoclonal antibody. By inhibiting this pathway, it helps clear skin plaques and improve symptoms.

Investigated diseases

Moderate to severe psoriasis - Psoriasis is a chronic skin condition that causes red, scaly patches to appear on the body. In moderate to severe forms, the patches cover a large area and may affect the scalp, elbows, knees, and lower back. The disease often begins with small, isolated lesions that gradually enlarge and merge over time. It tends to flare up periodically, with periods of worsening followed by partial improvement. Persistent inflammation can lead to thickened skin and increased discomfort. The condition usually persists for many years, with the extent of skin involvement changing throughout the course of the disease.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-527347-17-00Protocol codeM26-507Estimated enrolment105 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.